Evidence map›Paper›PMID 19119312›Full record

ReviewInternational journal of biological sciences2009

BRCA1, hormone, and tissue-specific tumor suppression.

Yanfen Hu

Open access · goldAbstract readReview
In one paragraph

Review in International journal of biological sciences, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Tissue-specific tumor suppression by BRCA1.Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Biosensors: the new wave in cancer diagnosis.Nanotechnology, science and applications · 2010
    Review
  19. Mouse models of inherited cancer syndromes.Hematology/oncology clinics of North America · 2010
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Yanfen HuDepartment of Molecular Medicine/Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78245, USA. huy3@uthscsa.edu
The University of Texas Health Science Center at San Antonio · US

Funding

The Mechanism of BRCA1 in Tumor SuppressionR01CA118578 · NCI · UNIVERSITY OF VIRGINIA · PI HU, YANFEN · 2006 to 2010
$1.1M
NCI NIH HHS R01 CA118578NCI NIH HHS R01CA118578
6 · The paper itself

Abstract

Germline mutations of BRCA1 predispose women to breast and ovarian cancers. Elucidating molecular mechanism of tissue- and gender-specific phenomena in BRCA1-related tumors is a key to our understanding of BRCA1 function in tumor suppression. This review summarizes studies in recent years on the link between BRCA1 and estrogen/progesterone signaling pathways, as well as discusses various models underscoring a triangle relationship among BRCA1, estrogen and genome instability.

Indexed as

BRCA1 ProteinBreast NeoplasmsCell ProliferationEstrogensFemaleGenetic Predisposition to DiseaseGenomic InstabilityGerm-Line MutationHumansProgesteroneSignal TransductionBRCA1 ProteinBRCA1 protein, humanEstrogensProgesteroneBRCA1estrogengenome instability.tumor suppression

Identifiers

PMID19119312
PMCPMC2605575
OpenAlexW2101774988

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.